Previous 10 | Next 10 |
Image source: The Motley Fool. PTC Therapeutics Inc (NASDAQ: PTCT) Q3 2021 Earnings Call Oct 28, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: PTC Therapeutics Inc (PTCT) Q3 2021 Earnings Call Transcript
Shares of PTC Therapeutics (NASDAQ:PTCT) are modestly higher in after-hours trading after the company raised its revenue guidance for the year. PTC now expects full-year net product revenues from its Duchenne muscular dystrophy franchise to be between $400M and $420M, up from between $370M an...
PTC Therapeutics (NASDAQ:PTCT): Q3 GAAP EPS of -$1.89 misses by $0.40. Revenue of $138.7M (+17.1% Y/Y) beats by $19.83M. Press Release For further details see: PTC Therapeutics EPS misses by $0.40, beats on revenue
PTC Therapeutics Provides a Corporate Update and Reports Third Quarter 2021 Financial Results - Total quarterly revenue of $139 million; 17% increase over third quarter 2020 - - Raises 2021 DMD franchise revenue guidance to $400-$420M from $370-$390M - - Continues to adv...
PTC Announces Expansion of Translarna™ Label to Include Ambulatory Patients as Young as 2 Years Old in Brazil PR Newswire SOUTH PLAINFIELD, N.J. , Oct. 25, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Brazilian N...
PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2021 Financial Results PR Newswire SOUTH PLAINFIELD, N.J. , Oct. 14, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference ...
PTC Therapeutics Celebrates Opening of Gene Therapy Manufacturing Facility -- Expansion in New Jersey supports company's robust gene therapy pipeline to address devastating rare disorders -- PR Newswire SOUTH PLAINFIELD, N.J. , Oct. 14, 2021 /PRNewswire/ -- P...
Tegsedi® Receives Innovative Drug Category Pricing in Brazil PR Newswire SOUTH PLAINFIELD, N.J. , Oct. 11, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Tegsedi ® (inotersen) has successfully received Category 1 cla...
Biogen is one of the leading providers of medicines used for the treatment of multiple sclerosis, spinal muscular atrophy. Biogen's gross margin is around 83.4%, significantly higher than the medical industry average and one of the highest among the top 20 pharmaceutical companies in ...
Results Show Long-Lasting and Holistic Improvements in Children with AADC Deficiency Treated with PTC-AADC Gene Therapy - Analysis of Five-Year Results Presented at 50th Child Neurology Society Annual Meeting - PR Newswire SOUTH PLAINF...
News, Short Squeeze, Breakout and More Instantly...
PTC Therapeutics Inc. Company Name:
PTCT Stock Symbol:
NASDAQ Market:
PTC Therapeutics Inc. Website:
PTC Therapeutics Announces Sepiapterin NDA Submission to FDA PR Newswire WARREN, N.J. , July 30, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the submission of the sepiapterin NDA to the U.S. FDA. The NDA submission is for the t...
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2024 Financial Results PR Newswire WARREN, N.J. , July 25, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to r...
2024-07-12 10:00:03 ET Jeffrey Hung from Morgan Stanley issued a price target of $32.00 for PTCT on 2024-07-12 08:15:00. The adjusted price target was set to $32.00. At the time of the announcement, PTCT was trading at $33.2. The overall price target consensus is at $43....